© 2018 Elsevier Inc. All rights reserved. Preliminary candidate gene and genome-wide association studies (GWAS) suggest that susceptibility to adverse perioperative events, including cardiac (myocardial infarction, ventricular dysfunction, atrial fibrillation), neurologic, and renal (among others) is genetically determined. Potential applications of biomarkers in perioperative medicine and critical care include prognosis, diagnosis, and monitoring of adverse outcomes, as well as informing and refining therapeutic decisions. So far, very few have been rigorously evaluated to demonstrate additive performance to existing risk stratification models (clinical validity) or change therapy (clinical utility). Most promising among those are natriuretic peptides and C-reactive protein for predicting risk of major adverse cardiovascular events, and procalcitonin to assess infection in the critically ill.
- Genomic and Precision Medicine: Cardiovascular Disease: Third Edition
Start / End Page
International Standard Book Number 13 (ISBN-13)
Digital Object Identifier (DOI)